Aktis Oncology AKTS
Drug Manufacturers - General, Healthcare
$14.59
−8.41%
- Market cap
- $811.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $1.4M | $1.6M | $3.2M | $3.4M | |
| R&D | $15.9M | $18.6M | $20M | $25.3M |
| SG&A | $3.7M | $3.9M | $5.9M | $7M |
| −$18.1M | −$21M | −$22.7M | −$28.9M | |
| Net income | −$15M | −$18.1M | −$18.3M | −$24.1M |
| −$18.60 | −$22.39 | −$0.38 | −$0.44 | |
| 805.8K | 807.3K | 48.6M | 55.3M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Aktis Oncology's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AKTSAktis Oncology | $811.5M | n/m | n/a | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| Peer median | $781.2M | 13.8× | 17.0× | 1.8× | +6% | 11.2% |
Investors who own it
Investors we follow who held Aktis Oncology at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolionew
More on Aktis Oncology
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .